Cognos Announces U.S. Patent Award for Cerebral Microdialysis

Grand News Network | November 6, 2023

INGLEWOOD, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cognos Therapeutics, Inc. ("Cognos" or the "Company"), a medical technology company focused on developing implantable smart pump technology, today announced its U.S. patent award covering an apparatus for microdialysis of the brain, which the Company intends to develop for treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, multiple sclerosis, and brain cancer using the Cognos' Sinnais™ implantable smart pump technology platform.

"We are pleased that the U.S. Patent Office has yet again recognized the uniqueness of our technology and granted this patent, which we hope paves the way for an advanced, fourth modality of treatment that more directly attacks neurological targets at the source, unlike drugs that cannot adequately get to the brain region due to the blood brain barrier. We hope that our patent will eventually enable safer and more effective treatment of neurological diseases, such as Alzheimer's," said Frank Adell, Chief Executive Officer of Cognos.

Cognos intends to develop the patented technology to enable cerebrospinal fluid ("CSF") dialysis, where CSF is filtered from protein debris. The Company plans to pursue this development in parallel with its primary focus of developing Sinnais™ to enable pharmaceutical companies to deliver drugs directly to the brain region by bypassing the blood-brain barrier.

Cognos anticipates that CSF dialysis will involve (i) a catheter placed into the ventricle of the patient's brain, (ii) an implantable pump capable of transporting CSF containing diseased cells associated with the neurodegenerative condition and (iii) an implantable separation device capable of dialyzing the CSF to remove circulating diseased cells and return clean CSF back to the brain. "In a healthy patient, CSF is typically clear and free from protein aggregates and debris. We are developing a microdialyzer to maintain the clarity and cleanliness of CSF in Alzheimer's patients by effectively removing protein aggregates such as beta-amyloid and tau proteins. We are currently in the early stages of development and are gearing up to initiate the first phase of proof of concept for our brain dialysis concept, scheduled to commence next year. We are excited about the potential impact our technology could have on Alzheimer's patients and their families," concluded Mr. Adell.

According to a 2023 GlobalData analysis, the global market for Alzheimer's disease is projected to grow at a compound annual rate of 20.0% from $2.2 billion in 2020 to $13.7 billion in 2030. It remains an area of immense interest for both the pharmaceutical and medical device industries. In the United States alone, the prevalence of Alzheimer's disease affects over 6 million people, making it one of the most common neurodegenerative conditions. The economic impact is staggering, with annual costs for care and treatment reaching hundreds of billions of dollars. On a global scale, Alzheimer's disease touches the lives of approximately 50 million individuals, and this number is expected to rise with the aging population.

Cognos has an extensive portfolio of patents and patent applications covering all key products, with over 30 exclusively owned patents that cover jurisdictions in the U.S., Canada, Mexico, China, Europe, Australia, and Japan.

About Cognos Therapeutics, Inc.
California-based ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner